Amanta Healthcare Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹607 Cr

SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28. FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost.

From Amanta Healthcare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹196

Market Cap

₹607 Cr

P/E Ratio

39.6

How does Amanta Healthcare Ltd rank in Pharmaceuticals & Biotechnology?

Compare Amanta Healthcare Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Amanta Healthcare Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹6 Cr.

Full financials →

📊 Revenue & Sales Performance

→SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28.
→New product pipeline of 20 products in inhalation and ophthalmic segments to commercialize in FY27-28, supporting growth.
→Export revenue grew from 32% in FY25 to 39% in FY26; active marketing in 25-30 countries with key markets including UK, Thailand, Philippines, South Sudan.
→Export markets like East Africa show cyclical buying patterns; export sales generally stronger in H2.
→Domestic IV fluid demand growing at 8-10% year-on-year, with two-port systems growing faster at 12-13%.
→Capacity ramp-up expected to reach full utilization within 3-4 months post commissioning, driving scale and margin expansion.
→Solar power project to reduce costs and boost profitability from FY27 onwards.
→Overall, growth driven by capacity expansion, new specialized products, and export market expansion.

📈 Profitability & Margins

→FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost.
→SteriPort expansion expected to increase EBITDA margin from 22% to around 24-25% with a 27% EBITDA margin from the new SteriPort line.
→SteriPort line commissioning by June-end, expected contribution of INR 80-85 crores revenue in FY27 (three quarters), with full impact INR 110-120 crores in FY28.
→PAT margin of 5-6% sustainable short-term; expected to improve by at least 3% post-leveraging.
→Growth driven by expanding higher-value product lines like SteriPort, inhalation solutions, and ophthalmic products with 20 products in pipeline.
→Lower finance cost due to debt refinancing and repayment expected to disproportionately boost PAT growth versus EBITDA.
→Overall, steady revenue growth, margin expansion, and improved profitability projected through product portfolio and capacity expansions.

🏗️ Capital Expenditure Plans

- SteriPort expansion: Commissioning expected by June 2026, aiming for operational by June 20; will add approx. INR110-120 crore top line from FY27 onwards with EBITDA margin around 27%. - SVP (Small Volume Parenteral) line: To be commissioned in late 2026 (October-December), focusing on inhalation and ophthalmic product pipelines, expected commercialization in FY27-28. - Solar power project: 10.8 MW captive solar plant to be commissioned by May 2026, expected to reduce power costs by about INR75 lakh per month starting FY27, improving cost efficiency and ESG profile. - Product pipeline: Currently developing 20 products primarily in inhalation and ophthalmic segments to enhance higher-margin and specialized products. - Focus on regulatory approvals and portfolio expansion to enter regulated markets alongside semi-regulated and emerging markets. These strategic investments aim to drive revenue growth, margin expansion, and operational efficiencies in upcoming years.

💰 Fundraising & Capital Structure

- The company has recently completed a refinancing exercise post-IPO, replacing higher-cost debt with lower-cost borrowings, resulting in a significant reduction in finance cost. - Currently, about 90% of the company's borrowings are at single-digit interest rates. - The total debt as of March 26 was INR 234 crore, which has reduced to INR 204 crore in early April after repayment. - Management expects to further replace around INR 30 crore to INR 40 crore of existing debt with cheaper debt within the next six months. - There is no mention of any ongoing or planned equity fundraising. - The company remains focused on maintaining a disciplined balance sheet while investing for long-term growth. Hence, while the company is actively managing and reducing its debt cost, no specific new debt or equity fundraising is announced or planned immediately.

📋 Order Book & Pipeline

→Amanta Healthcare Limited does not maintain a long-term order book extending over one year.
→Export orders are rolling and cyclic, with visibility of around 3 to 6 months in some markets.
→For example, the East African market's significant purchases happen from September to March, and export numbers tend to be better in H2 than H1.
→Markets like Southeast Asia show consistent order patterns throughout the year.
→The management currently does not have exact quantified numbers for the next quarter's order book but may share it separately.
→The company operates primarily on distributor-based orders rather than fixed long-term contracts.

Key Metrics

What Amanta Healthcar's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharma. (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
Sai Parenteral's (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

Frequently Asked Questions

What were Amanta Healthcare Ltd Q4 FY26 results?

What is Amanta Healthcare Ltd share price analysis?

Amanta Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 39.6 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.

Is Amanta Healthcare Ltd planning capital expenditure?

SteriPort expansion: Commissioning expected by June 2026, aiming for operational by June 20; will add approx.

Keep Amanta Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.